Palmitate-induced insulin resistance causes actin filament stiffness and GLUT4 mis-sorting without altered Akt signalling.


Journal

Journal of cell science
ISSN: 1477-9137
Titre abrégé: J Cell Sci
Pays: England
ID NLM: 0052457

Informations de publication

Date de publication:
01 11 2023
Historique:
received: 02 05 2023
accepted: 25 09 2023
medline: 9 11 2023
pubmed: 10 10 2023
entrez: 10 10 2023
Statut: ppublish

Résumé

Skeletal muscle insulin resistance, a major contributor to type 2 diabetes, is linked to the consumption of saturated fats. This insulin resistance arises from failure of insulin-induced translocation of glucose transporter type 4 (GLUT4; also known as SLC2A4) to the plasma membrane to facilitate glucose uptake into muscle. The mechanisms of defective GLUT4 translocation are poorly understood, limiting development of insulin-sensitizing therapies targeting muscle glucose uptake. Although many studies have identified early insulin signalling defects and suggest that they are responsible for insulin resistance, their cause-effect has been debated. Here, we find that the saturated fat palmitate (PA) causes insulin resistance owing to failure of GLUT4 translocation in skeletal muscle myoblasts and myotubes without impairing signalling to Akt2 or AS160 (also known as TBC1D4). Instead, PA altered two basal-state events: (1) the intracellular localization of GLUT4 and its sorting towards a perinuclear storage compartment, and (2) actin filament stiffness, which prevents Rac1-dependent actin remodelling. These defects were triggered by distinct mechanisms, respectively protein palmitoylation and endoplasmic reticulum (ER) stress. Our findings highlight that saturated fats elicit muscle cell-autonomous dysregulation of the basal-state machinery required for GLUT4 translocation, which 'primes' cells for insulin resistance.

Identifiants

pubmed: 37815440
pii: 330763
doi: 10.1242/jcs.261300
pii:
doi:

Substances chimiques

Palmitates 0
Proto-Oncogene Proteins c-akt EC 2.7.11.1
Glucose Transporter Type 4 0
Insulin 0
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : CIHR
ID : FDN-143203
Pays : Canada

Informations de copyright

© 2023. Published by The Company of Biologists Ltd.

Déclaration de conflit d'intérêts

Competing interests The authors declare no competing or financial interests.

Auteurs

Victoria L Tokarz (VL)

Department of Physiology, University of Toronto, Ontario, M5S 1A8, Canada.
Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada.

Sivakami Mylvaganam (S)

Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada.
Department of Biochemistry, University of Toronto, Ontario, M5S 1A8, Canada.

Amira Klip (A)

Department of Physiology, University of Toronto, Ontario, M5S 1A8, Canada.
Department of Biochemistry, University of Toronto, Ontario, M5S 1A8, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH